Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cellnon-Hodgkin’s lymphoma: a single institution study
| Autor: | Felix Reyes, Jean-Pierre Farcet, M.H. Delfau-Larue, Youlia M. Kirova, T. Elgnaoui, J.-L. Beaumont, F. Beaujean, Isabelle Gaillard, Corinne Haioun, C. Pautas, Karim Belhadj, P. Gaulard, A. Allain |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Adult
Male Oncology medicine.medical_specialty Lymphoma B-Cell medicine.medical_treatment Antigens CD34 Antineoplastic Agents Lymphoma Mantle-Cell Transplantation Autologous Antibodies Monoclonal Murine-Derived Internal medicine medicine Humans Lymphoma Follicular B cell Salvage Therapy Peripheral Blood Stem Cell Transplantation business.industry Stem Cells Bone Marrow Purging Remission Induction Antibodies Monoclonal Hematology Immunotherapy Middle Aged medicine.disease Combined Modality Therapy Hematopoietic Stem Cell Mobilization Surgery Non-Hodgkin's lymphoma Lymphoma Regimen Treatment Outcome medicine.anatomical_structure Molecular Response Female Rituximab Neoplasm Recurrence Local Stem cell business Follow-Up Studies medicine.drug |
| Zdroj: | Annals of Oncology. 15:504-510 |
| ISSN: | 0923-7534 |
| DOI: | 10.1093/annonc/mdh090 |
| Popis: | Background Rituximab induces clinical response in advanced B-cell lymphoma and is efficient in removing circulating B-cell from peripheral blood. We therefore postulated that rituximab might be a useful in vivo purging agent before high-dose therapy in this setting. Patients and methods Fourteen patients with relapsed follicular, marginal zone and mantle cell lymphomas (11, two and one cases, respectively) and a PCR-detectable molecular marker were treated first with rituximab, then a mobilization chemotherapeutic regimen, followed by high-dose therapy with peripheral blood stem cell transplantation. PCR analyses were performed in peripheral blood before rituximab and during follow-up, and in harvest. Results Harvests were free of PCR-detectable molecular marker in nine of the 11 studied cases (82%). After high-dose therapy, clinical complete remission was obtained in 13 (93%) patients and molecular remission in 11 (79%). With a median follow-up of 3 years, the 14 transplanted patients were alive, 11 of them remaining in clinical complete remission and eight in molecular remission at last follow-up. Conclusion Rituximab treatment followed by high dose therapy appears to be effective in achieving complete clinical and molecular response. In vivo harvest purging is predictive of prolonged clinical and molecular remission. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|